Influence of pharmacists' attitudes on adverse drug reaction reporting: A case-control study in Portugal

Drug Safety

Volumn 29, Issue 4, 2006, Pages 331-340

  Herdeiro, Maria T ^a,b   Figueiras, Adolfo ^a,e   Polónia, Jorge ^c   Gestal Otero, J J ^a,d  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

^c University of Porto   (Portugal)

^d Instituto de Salud Carlos III   (Spain)

^e UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL PHARMACY; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; HUMAN EXPERIMENT; INTERVIEW; MALE; PHARMACIST ATTITUDE; PORTUGAL; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; QUESTIONNAIRE; VISUAL ANALOG SCALE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ATTITUDE OF HEALTH PERSONNEL; CASE-CONTROL STUDIES; PHARMACISTS; PORTUGAL;

EID: 33645462842     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200629040-00004     Document Type: Article

References (46)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalised patients. JAMA 1998; 279: 1200-5
2. Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993; 27: 832-40
3. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 3; 329: 15-9
4. Beijer HJM, Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002; 24: 46-54
5. Rawlins MD. Pharmacovigilance: paradise lost, regained or postponed? J R Coll Physicians Lond 1995; 29: 41-9
6. Martin RM, Kapoor KV, Wilton LV, et al. Underreporting of suspected adverse drug reactions to newly marketed "black triangle" drugs in general practice: observational study. BMJ 1998; 317: 119-20
7. Backstrom M, Mjorndal T, Dahlqvist R. Under-reporting of serious adverse drug reactions in Sweden. Pharmacoepidemiol Drug Saf 2004; 13: 483-7
8. Mittmann N, Knowles SR, Gomez M, et al. Evaluation of the extent of under-reporting of serious adverse drug reactions: the case of toxic epidermal necrolysis. Drug Saf 2004; 27: 477-87
9. Instituto Nacional da Farmácia e do Medicamento (INFARMED). Farmacovigilância em Portugal. Lisboa: INFARMED, 2003
10. Generali JA, Danish MA, Rosenbaum SE. Knowledge of and attitudes about adverse drug reaction reporting among Rhode Island pharmacists. Ann Pharmacother 1995; 29: 365-9
11. Lee KKC, Chan TYK, Raymond K, et al. Pharmacists' attitudes toward adverse drug reaction reporting in Hong Kong. Ann Pharmacother 1994; 28: 1400-3
12. Roberts PI, Wolfson DJ, Booth TG. The role of pharmacists in adverse drug reaction reporting. Drug Saf 1994; 11: 7-11
13. Fincham JE. Adverse drug reaction reporting and pharmacists. J Clin Pharm Ther 1989; 14: 79-81
14. Van Grootheest AC, Van Puijenbroek EP, Jong-van den Berg LTW. Contribution of pharmacists to the reporting of adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11: 205-10
15. Green CG, Mottram DR, Raval D, et al. Community pharmacists' attitudes to adverse drug reaction reporting. Int J Pharm Pract 1999; 7: 92-9
16. Emerson A, Martin RM, Tomlin M, et al. Prospective cohort study of adverse events monitored by hospital pharmacists. Pharmacoepidemiol Drug Saf 2001; 10: 95-103
17. Forster AJ, Halil RB, Tierney MG. Pharmacist surveillance of adverse drug events. Am J Health Syst Pharm 2004; 61: 1466-72
18. Sinclair HK, Bond CM, Hannaford PC. Pharmacovigilance of over-the-counter products based in community pharmacy: a feasible option? Pharmacoepidemiol Drug Saf 1999; 8: 479-91
19. Barnes J. Pharmacovigilance of herbal medicines: a UK perspective. Drug Saf 2003; 26: 829-51
20. van Grootheest AC. Improving pharmacovigilance and the role of the pharmacist [thesis]. Groningen: University of Groningen, 2003
21. Green CF, Mottram DR, Rowe P, et al. An investigation into adverse drug reaction monitoring by United Kingdom hospital pharmacy departments. Int J Pharm Pract 1997; 5: 202-8
22. Sweis D, Wong ICK. A survey on factors could affect adverse drug reaction reporting according to hospital pharmacists in Great Britain. Drug Saf 2000; 23: 165-72
23. van Grootheest K, Olsson S, Couper M, et al. Pharmacists' role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiol Drug Saf 2004; 13: 457-64
24. Ahmad SR, Freiman JP, Graham DJ, et al. Quality of adverse drug experience reports submitted by pharmacists and physicians to the FDA. Pharmacoepidemiol Drug Saf 1996; 5: 1-7
25. Williams D, Feely J. Underreporting of adverse drug reaction attitudes of Irish doctors. Ir J Med Sci 1999; 168: 257-61
26. Rogers AS, Israel E, Smith CR, et al. Physician knowledge, attitudes, and behaviour to reporting adverse drug events. Arch Intern Med 1988; 148: 1596-600
27. Figueiras A, Tato F, Fontainas J, et al. Influence of physicians' attitudes on reporting adverse drug events. Med Care 1999; 37: 809-14
28. Scott HD, Thatcher A, Rosenbaum SE, et al. Adverse drug reaction reporting systems: the United Kingdom and the United States. R I Med J 1988; 71: 179-84
29. Bateman DN, Sanders GLS, Rawlins MD. Attitudes to adverse drug reaction reporting in the Northern Region. Br J Clin Pharmacol 1992; 34: 421-6
30. Belton KJ, Lewis SC, Payne S, et al. Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol 1995; 39: 223-6
31. Belton KJ. Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. Eur J Clin Pharmacol 1997; 52: 423-7
32. Herdeiro MT, Figueiras A, Polónia J, et al. Physicians' attitudes and adverse drug reaction reporting: a case-control study in Portugal. Drug Saf 2005; 28 (9): 825-33
33. Green FC, Mottram DR, Rowe PH, et al. Attitudes and knowledge of hospital pharmacists to adverse drug reaction reporting. Br J Clin Pharmacol 2001; 51: 81-6
34. Eland IA, Belton KJ, Van Grootheest AC, et al. Attitudinal survey of voluntary reporting of adverse drug reactions. Br J Clin Pharmacol 1999; 48: 623-7
35. Backstrom M, Mjorndal T, Dahlqvist R. Attitudes to reporting adverse drug reactions in northern Sweden. Eur J Clin Pharmacol 2000; 56: 729-32
36. Inman WHW. Assessment drug safety problems. In: Gent M, Shigmatsu I, editors. Epidemiological issues in reported drug-induced illnesses. Honolulu (ON): McMaster University Library Press, 1976: 17-24
37. Grant S, Aitchison T, Henderson E, et al. A comparison of the reproducibility and the sensitivity to change of visual analogue scales, Borg scales, and Likert scales in normal subjects during submaximal exercise. Chest 1999; 116: 1208-17
38. Lee A, Bateman DN, Edwards C, et al. Reporting of adverse drug reactions by hospital pharmacists: pilot scheme. BMJ 1997; 315 (7107): 519
39. Fincham J. A statewide program to stimulate reporting of adverse drug reactions. J Pharm Pract 1989; 4: 239-44
40. Taras-Zasowski KM, Einarson TR. Review of Canadian pharmacist involvement in adverse drug reaction reporting. Can J Hosp Pharm 1989; 42: 105-9
41. Calvert RT. Clinical pharmacy: a hospital perspective. Br J Clin Pharmacol 1999; 47: 231-8
42. Herdeiro MT, Polonia J, Gestal-Otero JJ, et al. Factors that influence spontaneous reporting of adverse drug reactions: a model centralized in the medical professional. J Eval Clin Pract 2004; 10: 483-9
43. Inman WHW. Attitudes to adverse drug reaction reporting. Br J Clin Pharmacol 1996; 41: 434-5
44. Cox AR, Marriott JF, Wilson KA, et al. Adverse drug reaction teaching in UK undergraduate medical and pharmacy programmes. J Clin Pharm Ther 2004; 29: 31-5
45. Moore N. The role of the clinical pharmacologist in the management of adverse drug reactions. Drug Saf 2001; 24: 1-7
46. Figueiras A, Montes A, Gestal-Otero JJ. Participación de los médicos en encuestas por correo [letter]. Med Clin (Barc) 1994; 103: 719